大分割立体定向放疗联合全脑放疗治疗脑转移瘤患者的回顾性研究
该回顾性研究纳入2018年5月至2020年7月50例脑转移瘤患者(111个病灶),接受HFSRT(18 Gy/3F)联合WBRT(40 Gy/20F)。颅内客观缓解率(RECIST 1.1)为62.1%,(RANO-BM)为58.6%;颅内局部控制率为93.1%,6个月和12个月iLC率分别为90.8%和57.4%。中位总生存期13.6个月,未观察到3级及以上急性毒性。
要点
- HFSRT(18 Gy/3F)联合WBRT(40 Gy/20F)治疗脑转移瘤,颅内局部控制率93.1%。
- 中位生存期13.6个月,KPS≥70患者为16.5个月,未观察到3级及以上急性毒性。
- 多因素分析显示性别、KPS评分和 gross tumor volume 是生存的显著影响因素。
核心结论
- HFSRT联合WBRT是脑转移瘤患者安全有效的局部治疗方式。
研究设计与样本
- 回顾性研究,纳入2018年5月至2020年7月50例脑转移瘤患者(111个病灶),接受HFSRT(18 Gy/3F)联合WBRT(40 Gy/20F)。
主要发现
- RECIST 1.1和RANO-BM标准评估的颅内客观缓解率分别为62.1%和58.6%。
- 颅内局部控制率为93.1%,6个月和12个月iLC率分别为90.8%和57.4%。
- 中位颅内无进展生存期未达到(范围0-23个月)。
- 6、12、24个月总生存率分别为74.2%、58.2%和22.9%;KPS≥70患者分别为83.8%、70.5%和29.7%。
- 全部患者和KPS≥70患者的中位生存时间分别为13.6个月和16.5个月。
关键数值与推荐
- 单因素分析中KPS评分对生存有统计学意义。
- 多因素分析中性别、KPS评分和gross tumor volume是生存的显著因素。
- 总生存与RPA、SIR、BS-BM和GGS分级显著相关。
- 未观察到3级及以上急性毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the clinical outcomes of hypofractionated stereotactic radiotherapy (HFSRT) combined with whole brain radiotherapy (WBRT) in patients with brain metastases (BMs). MATERIALS AND METHODS: From May 2018 to July 2020, 50 patients (111 lesions) received HFSRT (18 Gy/3F) + WBRT (40 Gy/20F). The RECIST 1.1 and RANO-BM criteria were used to evaluate treatment efficacy. Five prognostic indexes (RPA, GPA, SIR, BS-BM, and GGS) were applied. The primary endpoint was intracranial local control (iLC). Secondary endpoints were overall survival (OS) and the safety of treatment. RESULTS: Intracranial objective response rates (iORR) using the RECIST 1.1 and RANO-BM criteria were 62.1% and 58.6%, respectively. The iLC rate was 93.1%, the 6- and 12-month iLC rates were 90.8% and 57.4%, respectively. The median intracranial progression-free survival (iPFS) was not reached (range 0-23 months). The 6-, 12-, and 24-month OS rates were 74.2%, 58.2%, and 22.9%, respectively. The KPS score showed statistical significance in univariate analysis of survival. The 6, 12, and 24 month OS rates for patients with KPS ≥ 70 were 83.8%, 70.5%, and 29.7%, respectively. The median survival time (MST) for all patients and for patients with KPS ≥ 70 were 13.6 and 16.5 months, respectively. Sex, KPS score, and gross tumor volume were significant factors in the multivariate analysis of survival. OS was significantly associated with RPA, SIR, BS-BM, and GGS classes. No acute toxicities of grade 3 or higher were noted. CONCLUSION: HFSRT combined with WBRT is a safe and effective local treatment modality for BM patients.
引用
- Xie XY, Peng HH, Zhang X, et al. Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases. Radiat Oncol. 2022. PMID: 35883147. doi:10.1186/s13014-022-02096-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。